A story that ran in the Aug. 13, 2004, issue of BioWorld Today stated that Ardent Pharmaceuticals Inc. partner NV Organon had completed a Phase II trial of DPI-3290 for acute post-operative pain. Ardent and Organon dissolved their partnership late last year.

Editor's Note: The correction has been made in BioWorld Online